Back to Search Start Over

Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases

Authors :
Wesdorp, Nina J
Kemna, Ruby
Bolhuis, Karen
van Waesberghe, Jan H T M
Nota, Irene M G C
Struik, Femke
Oulad Abdennabi, Ikrame
Phoa, Saffire S K S
van Dieren, Susan
van Amerongen, Martinus J
Chapelle, Thiery
Dejong, Cornelis H C
Engelbrecht, Marc R W
Gerhards, Michael F
Grünhagen, Dirk
van Gulik, Thomas M
Hermans, John J
de Jong, Koert P
Klaase, Joost M
Liem, Mike S L
van Lienden, Krijn P
Molenaar, I Quintus
Patijn, Gijs A
Rijken, Arjen M
Ruers, Theo M
Verhoef, Cornelis
de Wilt, Johannes H W
Swijnenburg, Rutger-Jan
Punt, Cornelis J A
Huiskens, Joost
Stoker, Jaap
Kazemier, Geert
Surgery
MUMC+: MA Heelkunde (9)
RS: NUTRIM - R2 - Liver and digestive health
Internal medicine
Radiology and nuclear medicine
AGEM - Re-generation and cancer of the digestive system
VU University medical center
CCA - Imaging and biomarkers
Radiology & Nuclear Medicine
Graduate School
AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
Radiology and Nuclear Medicine
AGEM - Digestive immunity
APH - Methodology
Oncology
Groningen Institute for Organ Transplantation (GIOT)
Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Value, Affordability and Sustainability (VALUE)
Source :
Radiology. Imaging cancer, 4(3):e210105. Radiological Society of North America Inc., Radiology: Imaging Cancer, 4(3):e210105. Radiological Society of North America Inc., Radiology-imaging cancer, Radiol Imaging Cancer, Radiology: Imaging Cancer, 4, Dutch Colorectal Liver Expert Panel 2022, ' Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases ', Radiology: Imaging Cancer, vol. 4, no. 3, e210105, pp. e210105 . https://doi.org/10.1148/rycan.210105, Radiology: Imaging Cancer, 4, 3, Radiology. Imaging cancer, 4(3):e210105
Publication Year :
2022
Publisher :
Radiological Society of North America Inc., 2022.

Abstract

Item does not contain fulltext Purpose To evaluate interobserver variability in the morphologic tumor response assessment of colorectal liver metastases (CRLM) managed with systemic therapy and to assess the relation of morphologic response with gene mutation status, targeted therapy, and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 measurements. Materials and Methods Participants with initially unresectable CRLM receiving different systemic therapy regimens from the randomized, controlled CAIRO5 trial (NCT02162563) were included in this prospective imaging study. Three radiologists independently assessed morphologic tumor response on baseline and first follow-up CT scans according to previously published criteria. Two additional radiologists evaluated disagreement cases. Interobserver agreement was calculated by using Fleiss κ. On the basis of the majority of individual radiologic assessments, the final morphologic tumor response was determined. Finally, the relation of morphologic tumor response and clinical prognostic parameters was assessed. Results In total, 153 participants (median age, 63 years [IQR, 56-71]; 101 men) with 306 CT scans comprising 2192 CRLM were included. Morphologic assessment performed by the three radiologists yielded 86 (56%) agreement cases and 67 (44%) disagreement cases (including four major disagreement cases). Overall interobserver agreement between the panel radiologists on morphology groups and morphologic response categories was moderate (κ = 0.53, 95% CI: 0.48, 0.58 and κ = 0.54, 95% CI: 0.47, 0.60). Optimal morphologic response was particularly observed in patients treated with bevacizumab (P = .001) and in patients with RAS/BRAF mutation (P = .04). No evidence of a relationship between RECIST 1.1 and morphologic response was found (P = .61). Conclusion Morphologic tumor response assessment following systemic therapy in participants with CRLM demonstrated considerable interobserver variability. Keywords: Tumor Response, Observer Performance, CT, Liver, Metastases, Oncology, Abdomen/Gastrointestinal Clinical trial registration no. NCT02162563 Supplemental material is available for this article. © RSNA, 2022.

Details

Language :
English
ISSN :
2638616X and 02162563
Volume :
4
Issue :
3
Database :
OpenAIRE
Journal :
Radiology. Imaging cancer
Accession number :
edsair.doi.dedup.....b4769aff13cd9f3cb916e7eca8d5f3b1